M Parton

Summary

Country: UK

Publications

  1. ncbi High incidence of HER-2 positivity in inflammatory breast cancer
    M Parton
    Breast Unit, Royal Marsden Hospital Trust and Institute of Cancer Research, Fulham Rd, London SW3 6JJ, UK
    Breast 13:97-103. 2004
  2. ncbi Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer
    C D Archer
    Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 89:1035-41. 2003
  3. ncbi Is capecitabine efficacious in triple negative metastatic breast cancer?
    A A Kotsori
    Breast Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Oncology 79:331-6. 2010
  4. ncbi Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience
    T Waddell
    Breast Unit Royal Marsden Hospital, Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 104:1675-9. 2011
  5. ncbi The biology of neoadjuvant chemotherapy for breast cancer
    S Cleator
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Endocr Relat Cancer 9:183-95. 2002

Collaborators

Detail Information

Publications5

  1. ncbi High incidence of HER-2 positivity in inflammatory breast cancer
    M Parton
    Breast Unit, Royal Marsden Hospital Trust and Institute of Cancer Research, Fulham Rd, London SW3 6JJ, UK
    Breast 13:97-103. 2004
    ..Early HER-2 directed therapy (such as the monoclonal antibody trastuzumab) as a part of multimodal treatment may improve outcome in this poor prognosis cancer...
  2. ncbi Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer
    C D Archer
    Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 89:1035-41. 2003
    ..Pretreatment proliferation and GI are however predictive of response to chemotherapy in breast cancer...
  3. ncbi Is capecitabine efficacious in triple negative metastatic breast cancer?
    A A Kotsori
    Breast Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Oncology 79:331-6. 2010
    ..We have therefore retrospectively analysed capecitabine outcome in the TN subgroup of patients with locally advanced or metastatic breast cancer treated in our unit...
  4. ncbi Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience
    T Waddell
    Breast Unit Royal Marsden Hospital, Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 104:1675-9. 2011
    ..We have retrospectively evaluated the outcome of patients with HER-2+ve locally advanced (LA) or metastatic breast cancer (MBC) who continued T beyond PD, treated in our unit...
  5. ncbi The biology of neoadjuvant chemotherapy for breast cancer
    S Cleator
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Endocr Relat Cancer 9:183-95. 2002
    ..Continuing work using cDNA microarrays may yield new, more reliable indices of likely response and an improved insight into biological processes related to chemotherapeutic response...